Chlorpromazine Hydrochloride 200 mg Tablet, Coated, 100-count — NDC 23155-807-01 (Billing 23155-0807-01) · Product 23155-807
by Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. · 100 TABLET, COATED in 1 BOTTLE (23155-807-01)
NDC 23155-807-01 (billing 23155-0807-01) is a package of 100 tablets of Chlorpromazine Hydrochloride 200 mg Tablet, Coated from Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc., no longer marketed, no longer in the FDA NDC Directory; retail pharmacies pay about $0.6636 per tablet (NADAC). It is the main listing for product NDC 23155-807, its only package size.
NDC 23155-0807-01
🏷️ FDA NDC (as labeled)
23155-807-01
billing pads the product segment with a zero
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Mar 13, 2024 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →
⚠️
Other active recalls for Chlorpromazine Hydrochloride (different manufacturers) — 6 · tap to view
These affect other manufacturers’ products for the same ingredient — not necessarily the exact NDC on this page.
Class II · Sep 3, 2025 — CGMP Deviations: presence of N-Nitroso Desmethyl Chlorpromazine above the recommended acceptable intake limit (Zydus Pharmaceuticals (USA) Inc) · FDA recall D-0634-2025
Class II · Sep 3, 2025 — CGMP Deviations: presence of N-Nitroso Desmethyl Chlorpromazine above the recommended acceptable intake limit (Zydus Pharmaceuticals (USA) Inc) · FDA recall D-0630-2025
Class II · Sep 3, 2025 — CGMP Deviations: presence of N-Nitroso Desmethyl Chlorpromazine above the recommended acceptable intake limit (Zydus Pharmaceuticals (USA) Inc) · FDA recall D-0637-2025
Class II · Sep 3, 2025 — CGMP Deviations: presence of N-Nitroso Desmethyl Chlorpromazine above the recommended acceptable intake limit (Zydus Pharmaceuticals (USA) Inc) · FDA recall D-0633-2025
Class II · Sep 3, 2025 — CGMP Deviations: presence of N-Nitroso Desmethyl Chlorpromazine above the recommended acceptable intake limit (Zydus Pharmaceuticals (USA) Inc) · FDA recall D-0632-2025
Class II · Sep 3, 2025 — CGMP Deviations: presence of N-Nitroso Desmethyl Chlorpromazine above the recommended acceptable intake limit (Zydus Pharmaceuticals (USA) Inc) · FDA recall D-0639-2025
Each entry is an official FDA enforcement report — look up any recall number in the FDA recall database ↗
⚠️
Excluded from the active FDA NDC Directory.
The labeler reported this product as discontinued, so it is excluded from the active NDC Directory. The listing was last certified through Mar 2025. A label may still appear on DailyMed, but the NDC is no longer in the current FDA NDC Directory.
Search the FDA NDC Directory ↗
Identity & classification
Regulatory identifiers FDA, NLM and CMS codes for this package
FDA NDC (as labeled)
23155-807-01
Product NDC
23155-807
11-digit billing NDC
23155080701
NCPDP billing unit
EA — each (per item)
Application #
ANDA213590
Chemical class
Phenothiazine [EPC], Phenothiazines
DEA schedule
Non-controlled
Marketing category
ANDA
Marketing status
Discontinued
FDA listing status
Discontinued by firm (certified through Mar 2025)
Route
ORAL
Dosage form
TABLET, COATED
Substance
CHLORPROMAZINE HYDROCHLORIDE
TE code (Orange Book)
AB · RLD · RS
Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification
GCN Seq No
003798
GCN
14435
HICL code
001621
Ingredient (HICL)
Chlorpromazine Hcl
HIC1 code
H
Therapeutic class — broad (HIC1)
Nervous System (Except Autonomic)
HIC2 code
H2
Therapeutic class — intermediate (HIC2)
Psychoactive Drugs
HIC3 code
H2G
Therapeutic class — specific (HIC3)
Antipsychotics,Phenothiazines
AHFS code
28:16.08.24
AHFS class
Phenothiazines
FDB label name
CHLORPROMAZINE 200 MG TABLET
FDB brand name
Chlorpromazine Hcl
Legend status
F — Federal legend — prescription drug or device
Quick answers for NDC 23155-807-01
- GSN (GCN sequence number): 003798
- GCN: 14435
- HICL (First Databank): 001621
- AHFS class code: 28:16.08.24
- 11-digit billing NDC: 23155080701
Why two NDCs?
The FDA registers this code as 23155-807-01 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 23155-0807-01. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.
- FDA openFDA NDC Directory · synced Oct 1, 2026
- FDA label on DailyMed · label index refreshed Oct 1, 2026
- RxNorm (NLM RxNav) · catalog refreshed Sep 24, 2026
- Medi-Span GPI (licensed)
- First Databank (licensed) · refreshed Oct 1, 2026
Clinical
Label name CHLORPROMAZINE 200 MG TABLET Ingredient Chlorpromazine Hcl
📗 Our plain-language guide HelloPharmacist
- It treats schizophrenia and other psychotic disorders, and the manic type of manic-depressive illness. It is also used for severe nausea and vomiting, stubborn hiccups, and a few o...
- Take it exactly as prescribed. Your dose is usually raised gradually and later lowered to the lowest amount that works. Benefit for psychotic symptoms can take weeks or months, so...
- Drowsiness is common, especially in the first week or two. You may also have dizziness when standing, dry mouth, a stuffy nose, constipation or weight gain. Stand up slowly and be...
- Call right away for a sudden sore throat or fever, yellowing of the skin or eyes, or high fever with stiff muscles and confusion. Also call for uncontrolled movements of the face,...
Patient education
Supplement & herbal interactions
1
Nutrient depletion considerations
Chlorpromazine may be associated with lower levels of 1 nutrient — worth a chat with your pharmacist, not a cause for alarm.
An association is not a deficiency. Educational only — don't start or stop anything without professional guidance.
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.
- MedlinePlus (NLM) · refreshed Oct 1, 2026
- FDA label on DailyMed · label index refreshed Oct 1, 2026
💬 Questions about Chlorpromazine Hydrochloride?
Ask a pharmacist →
Ask a licensed pharmacist directly — free, answered by our team.
Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per ea | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | $0.664 | $66.36 / 100 tablets |
| Medicaid paysCMS SDUD · 12 mo | $1.46 | $146.14 / 100 tablets |
| Medicare drug plans payPart D · quarterly | No Part D plan price is available for this NDC in our data. | |
NADAC price history (per ea) — tap or hover for the price & month
▼ Down 35% over the last 10 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.
- CMS NADAC weekly file · file of Sep 30, 2026
- CMS ASP pricing files · refreshed Sep 20, 2026
- CMS Medicaid State Drug Utilization Data · through Q4 2025
- CMS Part D plan pricing files · refreshed Sep 24, 2026
- VA National Acquisition Center price file
Packaging — all sizes for this product
| Package NDC | Description | Marketing start | Marketing end | Status |
|---|---|---|---|---|
| 23155-0807-01 23155-807-01 You're viewing this Main listing | 100 TABLET, COATED in 1 BOTTLE (23155-807-01) | 2023-06-25 | — | Discontinued by firm |
Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Chlorpromazine Hydrochloride 200 mg 00527-2965-37 | Lannett | 100 tablets | $0.664 | AB | Availability likely | — |
| Chlorpromazine Hydrochloride 200 mg 00832-6021-00 | Upsher-Smith | 100 tablets | $0.664 | AB | Availability likely | — |
| Chlorpromazine Hydrochloride 200 mg 50268-0166-12 | AvPAK | 1 tablet | $0.664 | AB | Availability likely | — |
| Chlorpromazine Hydrochloride 200 mg 60687-0463-01 | American | 1 tablet | $0.664 | AB | Availability likely | — |
| Chlorpromazine Hydrochloride 200 mg 60687-0971-01 | American | 1 tablet | $0.664 | AB | Availability likely | — |
| chlorpromazine hydrochloride 200 mg 62135-0424-90 | Chartwell | 90 tablets | $0.664 | AB | Availability likely | — |
| Chlorpromazine Hydrochloride 200 mg 68462-0865-01 | Glenmark | 100 tablets | $0.664 | AB | Availability likely | — |
| Chlorpromazine Hydrochloride 200 mg 69238-1062-01 | Amneal | 100 tablets | $0.664 | AB | Availability likely | — |
| Chlorpromazine hydrochloride 200 mg 70710-1133-01 | Zydus | 100 tablets | $0.664 | AB | Availability likely | — |
| Chlorpromazine Hydrochloride 200 mg 72205-0107-91 | Novadoz | 100 tablets | $0.664 | AB | Availability likely | — |
| Chlorpromazine Hydrochloride 200 mgthis 23155-0807-01 | Heritage | 100 tablets | $0.664 | AB | Discontinued | — |
| Chlorpromazine hydrochloride 200 mg 16714-0051-01 | Northstar | 100 tablets | $0.842 | AB | Discontinued | +27% |
| ChlorproMAZINE Hydrochloride 200 mg 63304-0083-01 | Sun | 100 tablets | $0.842 | — | FDA listed | +27% |
| ChlorproMAZINE Hydrochloride 200 mg 90096-0135-01 | Zameer | 100 tablets | $1.428 | AB | FDA listed | +115% |
| Chlorpromazine 200 mg 46708-0739-10 | Alembic | 1000 tablets | — | AB | FDA listed | — |
| Chlorpromazine Hydrochloride 200 mg 51407-0438-01 | Golden | 100 tablets | — | AB | FDA listed | — |
| Chlorpromazine Hydrochloride 200 mg 59651-0571-01 | Aurobindo | 100 tablets | — | AB | FDA listed | — |
| Chlorpromazine 200 mg 62332-0739-10 | Alembic | 1000 tablets | — | AB | FDA listed | — |
| Chlorpromazine Hydrochloride 200 mg 70518-4142-00 | REMEDYREPACK | 1 tablet | — | AB | FDA listed | — |
| Chlorpromazine Hydrochloride 200 mg 70518-4295-00 | REMEDYREPACK | 1 tablet | — | AB | FDA listed | — |
| Chlorpromazine hydrochloride 200 mg 70771-1510-01 | Zydus | 100 tablets | — | AB | FDA listed | — |
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.
- FDA openFDA NDC Directory · synced Oct 1, 2026
- FDA Orange Book · refreshed Sep 3, 2026
- CMS NADAC weekly file · file of Sep 30, 2026
Availability & generic status
📍
2026
Currently FDA-listed
listed with the FDA
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug
This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.
Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.
- FDA Orange Book · refreshed Sep 3, 2026
Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
Loading inactive ingredients from the official FDA label in the background. No external source is being called by this page request.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured
IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.- FDA label on DailyMed · label index refreshed Oct 1, 2026
- FDA openFDA NDC Directory · synced Oct 1, 2026
Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.
Manufacturer & labeler
LabelerHeritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.
Application holderSOMERSET THERAPEUTICS LLC
FDA applicationANDA213590 (ANDA)
Labeler code23155
Product typeHuman Prescription Drug
Portfolio253 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.
- FDA openFDA NDC Directory · synced Oct 1, 2026
- Drugs@FDA
Full prescribing information FDA SPL
The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
📄 FDA label ▾
No FDA label is on file for this product yet. Labels load from openFDA / DailyMed and refresh weekly.
No label section mentions that — try another word, or open the full label on DailyMed below.
Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA.
Medicaid utilization & spend
📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for 23155-0807-01, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q4 2025 · 4 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
11
Units reimbursed last 4 qtrs
623
Gross reimbursed last 4 qtrs
$910.46
Avg / prescription
$82.77
Avg / unit
$1.4614
Latest quarter Q4 2025
0Rx
Medicaid pays / ea
$1.4614
gross reimbursed
vs
NADAC / ea
$0.6636
acquisition cost
=
Spread
+$0.7978
+120% vs cost
What Medicaid paid per ea (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
Fee-for-service · 11 Rx Managed care · 0 Rx
State Medicaid map
Units reimbursed · per 100k residents
12.212.2
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
Prescriptions—
Units—
Reimbursed—
🏆 Top states by units · per 100k residents
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.
Reported adverse events (FAERS)
Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Chlorpromazine hydrochloride — the ingredient across all brands.
Top reported reactions
Age at onset
Reporter sex
Male · 54%
Female · 46%
Unknown · 1%
Serious outcomes
Reports over time (by year) — tap or hover for the count & year
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.
About this NDC listing & data coverage
Finished prescription product
No longer marketed (per FDA listing data)
What data is (and isn’t) available for this NDC — tap to expand
| NDC identity (package / product / labeler codes) | ✓ Available |
| Labeler | ✓ Available |
| Product & package description | ✓ Available |
| Marketing category & status | ✓ Available |
| Active ingredient / dosage form / route | ✓ Available |
| FDA label (SPL via DailyMed) | — Not published for this NDC No structured label is linked to this listing in DailyMed/openFDA. |
| Package photos | — Not published for this NDC No photo available yet for this listing. |
| Inactive ingredients (structured) | — Not published for this NDC The labeler did not submit a structured excipient list, or no SPL is available. |
| NADAC pharmacy acquisition price (CMS) | ✓ Available |
| Orange Book / therapeutic-equivalence data | ✓ Available |
| HCPCS J-code billing crosswalk | — Not published for this NDC Most self-administered / retail products have no J-code — that is normal. |
| Medicaid utilization (CMS SDUD) | ✓ Available |
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.
Questions about this listing
Why is there no full label on this page?
No structured FDA label (SPL) is currently linked to this NDC in DailyMed/openFDA. That can happen with older listings, certain OTC and repackaged products, and recently updated listings whose label has not yet propagated. The listing itself is still valid — this page shows everything the public feeds provide for this package.
What does the discontinued status mean for this NDC?
The labeler reported a marketing end date (or the listing was delisted), so this specific package is no longer actively marketed. Remaining stock may still be dispensed for a time, and the NDC stays valid for historical records and claims — but data feeds (pricing, labeling) typically stop updating for it. Other package sizes or other manufacturers' versions of the same medication may still be marketed — see the equivalents section where available.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The FDA registers it as 23155-807-01, which is what is printed on the packaging and shown on DailyMed. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero: 23155-0807-01, written without dashes as 23155080701. The Identity section at the top of this page lists every form of this code.
What do the three segments of this NDC mean?
In 23155-0807-01, the first segment (23155) is the labeler code FDA assigned to Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.; the middle segment (0807) identifies this specific product — its ingredient, strength, and dosage form; and the last segment (01) identifies this exact package size and type. Together they name one specific package of one specific product.
Who lists this product with the FDA?
Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
Do I need a prescription for this product?
This NDC is listed with FDA as a prescription product, so it is dispensed under a prescriber's order. Your pharmacist can tell you whether any over-the-counter forms of the same medication exist.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
For educational and professional reference only — not medical advice. Pricing reflects published
NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.